OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press6310.17650/1818-8346-2012-7-2-57-66LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫMyelodysplastic syndromes: therapeutic problems and decisions (review)Миелодиспластические синдромы: терапевтические проблемы и решения (обзор литературы)SemochkinS. V.СемочкинС. В.
Russian Federation
semochkin_sv@rsmu.ruTolstykhT. N.ТолстыхТ. Н.
Russian Federation
RumyantsevA. G.РумянцевА. Г.
Russian Federation
D. Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology N.I. Pirogov Russian National Research Medical UniversityФедеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России Российский национальный медицинский исследовательский университет им. Н.И. Пирогова Минздрава РоссииD. Rogachev Federal Research Center of Pediatric Hematology, Oncology and ImmunologyФедеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России2205201272576622072014220720142012https://oncohematology.abvpress.ru/ongm/article/view/63

Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal disorders of myeloid hematopoietic stem cells characterized by an ineffective hematopoiesis associated with cytopenias, morphologic dysplasia and a progression to acute myeloid leukemia. The only potentially curative MDS treatment is hematopoietic stem cell transplantation, which is usually not even discussed because most patients with advanced age at diagnosis. Currently only three drugs are approved by US Food and Drug Administration (FDA) and European Medicines Agency for therapy of MDS. For low and intermediate-1 risk MDS del(5q) the novel immunomodulatory drug lenalidomide is asserted, and for intermediate-2 and high risk the two hypomethylating agents (azacitidine, decitabine) are approved. The results of completed clinical trials demonstrating the efficacy and safety of these agents are presented. The new data indicating that the successful future of MDS treatment rests in the combination of multiple treatments modalities to achieve improved clinical outcomes are discussed in this review.

myelodysplastic syndromeshypomethylating agentslenalidomideazacitidinedecytabineмиелодиспластический синдромленалидомидгипометилирующие агентыазацитидиндецитабин1. Rollison D.E., Howlader N., Smith M.T. et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008;112(1):45–52.Rollison D.E., Howlader N., Smith M.T. et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008;112(1):45–52.2. Кохно А.В., Паровичникова Е.Н., Савченко В.Г. Миелодиспластический синдром. Клин геронтол 2009;15(3):33–46.Кохно А.В., Паровичникова Е.Н., Савченко В.Г. Миелодиспластический синдром. Клин геронтол 2009;15(3):33–46.3. Sekeres M.A. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J Natl Compr Canc Netw 2011;9(1):57–63.Sekeres M.A. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J Natl Compr Canc Netw 2011;9(1):57–63.4. Aul C., Gattermann N., Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992;82(2):358–67.Aul C., Gattermann N., Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992;82(2):358–67.5. Rådlund A., Thiede T., Hansen S. et al. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 1995;54(3):153–6.Rådlund A., Thiede T., Hansen S. et al. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 1995;54(3):153–6.6. Maynadié M., Verret C., Moskovtchenko P. et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer 1996;74(2):288–90.Maynadié M., Verret C., Moskovtchenko P. et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer 1996;74(2):288–90.7. Steensma D.P., Tefferi A. Risk-based management of myelodysplastic syndrome. Oncology (Williston Park) 2007;21(1):43–54.Steensma D.P., Tefferi A. Risk-based management of myelodysplastic syndrome. Oncology (Williston Park) 2007;21(1):43–54.8. Hopfer O., Komor M., Koehler I.S. et al. DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineagespecific differentiation. Exp Hematol 2007;35(5):712–23.Hopfer O., Komor M., Koehler I.S. et al. DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineagespecific differentiation. Exp Hematol 2007;35(5):712–23.9. Владимирская Е.Б., Масчан A.A., Румянцев А.Г. Апоптоз и его роль в развитии опухолевого роста. Гематол и трансфузиол 1997;42(5):4–9.Владимирская Е.Б., Масчан A.A., Румянцев А.Г. Апоптоз и его роль в развитии опухолевого роста. Гематол и трансфузиол 1997;42(5):4–9.10. Epperson D.E., Nakamura R., Saunthararajah Y. et al. Oligoclonal T-cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001;25(12):1075–83.Epperson D.E., Nakamura R., Saunthararajah Y. et al. Oligoclonal T-cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001;25(12):1075–83.11. Sloand E.M. Hypocellular myelodysplasia. Hematol Oncol Clin North Am 2009;23(2):347–60.Sloand E.M. Hypocellular myelodysplasia. Hematol Oncol Clin North Am 2009;23(2):347–60.12. Calado R.T. Immunologic aspects of hypoplastic myelodysplastic syndrome. Semin Oncol 2011;38(5):667–72.Calado R.T. Immunologic aspects of hypoplastic myelodysplastic syndrome. Semin Oncol 2011;38(5):667–72.13. Bennett J.M., Catovsky D., Daniel M.T. t al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51(2):189–99.Bennett J.M., Catovsky D., Daniel M.T. t al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51(2):189–99.14. Vardiman J.W., Thiele J., Arber D.A. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114(5):937–51.Vardiman J.W., Thiele J., Arber D.A. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114(5):937–51.15. Greenberg P., Cox C., LeBeau M.M. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89(6): 2079–88.Greenberg P., Cox C., LeBeau M.M. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89(6): 2079–88.16. Malcovati L., Germing U., Kuendgen A. et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25(23):3503–10.Malcovati L., Germing U., Kuendgen A. et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25(23):3503–10.17. Schanz J., Tüchler H., Solé F. et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30(8):820–9.Schanz J., Tüchler H., Solé F. et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30(8):820–9.18. Al-Ameri A., Cherry M., Garcia-Manero G., Quintás-Cardama A. Standard therapy for patients with myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 2011;11(4):303–13.Al-Ameri A., Cherry M., Garcia-Manero G., Quintás-Cardama A. Standard therapy for patients with myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 2011;11(4):303–13.19. Hellström-Lindberg E., Gulbrandsen N., Lindberg G. et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120(6):1037–46.Hellström-Lindberg E., Gulbrandsen N., Lindberg G. et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120(6):1037–46.20. Ludwig H. Anemia of hematologic malignancies: what are the treatment options? Semin Oncol 2002;29(3 Suppl 8):45–54.Ludwig H. Anemia of hematologic malignancies: what are the treatment options? Semin Oncol 2002;29(3 Suppl 8):45–54.21. Passweg J.R., Giagounidis A.A., Simcock M. et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol 2011;29(3):303–9.Passweg J.R., Giagounidis A.A., Simcock M. et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol 2011;29(3):303–9.22. NCCN Clinical Practice Guidelines in Oncology™. Myelodysplastic Syndromes v 1.2012. Available at: http://www.nccn.org/professionals/ physician_gls/pdf/mds.pdf. Accessed March 9, 2012.NCCN Clinical Practice Guidelines in Oncology™. Myelodysplastic Syndromes v 1.2012. Available at: http://www.nccn.org/professionals/ physician_gls/pdf/mds.pdf. Accessed March 9, 2012.23. Грицаев С.В., Зотова И.И., Кострома И.И. и соавт. Миелодиспластический синдром и хелаторная терапия. Фарматека 2011;17(230):48–52.Грицаев С.В., Зотова И.И., Кострома И.И. и соавт. Миелодиспластический синдром и хелаторная терапия. Фарматека 2011;17(230):48–52.24. Семочкин С.В. Биологические основы применения иммуномодулирующих препаратов в лечении множественной миеломы. Онкогематол 2010;1:21–31.Семочкин С.В. Биологические основы применения иммуномодулирующих препаратов в лечении множественной миеломы. Онкогематол 2010;1:21–31.25. Raza A., Reeves J.A., Feldman E.J. et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111(1):86–93.Raza A., Reeves J.A., Feldman E.J. et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111(1):86–93.26. Sekeres M.A., Maciejewski J.P., Giagounidis A.A. et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008;26(36):5943–9.Sekeres M.A., Maciejewski J.P., Giagounidis A.A. et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008;26(36):5943–9.27. List A., Dewald G., Bennett J. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355(14): 1456–65.List A., Dewald G., Bennett J. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355(14): 1456–65.28. Fenaux P., Giagounidis A., Selleslag D. et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/ Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011;118(14):3765–76.Fenaux P., Giagounidis A., Selleslag D. et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/ Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011;118(14):3765–76.29. List A.F., Giagounidis A., Backstrom J.T. et al. Early lenalidomide (LEN) dose intensity and durable RBC-transfusion ndependence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q. 2011 ASCO nnual Meeting, Chicago, USA, 3–7 June 2011. J Clin Oncol 2011;29(suppl); abstr. 6522.List A.F., Giagounidis A., Backstrom J.T. et al. Early lenalidomide (LEN) dose intensity and durable RBC-transfusion ndependence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q. 2011 ASCO nnual Meeting, Chicago, USA, 3–7 June 2011. J Clin Oncol 2011;29(suppl); abstr. 6522.30. Creusot F., Acs G., Christman J. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'deoxycytidine. J Biol Chem 1982;257(4):2041–8.Creusot F., Acs G., Christman J. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'deoxycytidine. J Biol Chem 1982;257(4):2041–8.31. Christman J., Mendelsohn N., Herzog D. et al. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL- 60). Cancer Res 1983;43(2):763–9.Christman J., Mendelsohn N., Herzog D. et al. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL- 60). Cancer Res 1983;43(2):763–9.32. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148–59.Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148–59.33. Silverman L.R., McKenzie D.R., Peterson B.L. et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24(24): 3895–903.Silverman L.R., McKenzie D.R., Peterson B.L. et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24(24): 3895–903.34. Kantarjian H., Issa J.P., Rosenfeld C.S. et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106(8):1794–803.Kantarjian H., Issa J.P., Rosenfeld C.S. et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106(8):1794–803.35. Fenaux P., Mufti G.J., Hellstrom-Lindberg E. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10(3):223–32.Fenaux P., Mufti G.J., Hellstrom-Lindberg E. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10(3):223–32.36. Lübbert M., Suciu S., Baila L. et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011;29(15):1987–96.Lübbert M., Suciu S., Baila L. et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011;29(15):1987–96.37. Silverman L.R., Demakos E.P., Peterson B.L. et al. Randomized controlled trial of azacitidine in patients with the yelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20(10):2429–40.Silverman L.R., Demakos E.P., Peterson B.L. et al. Randomized controlled trial of azacitidine in patients with the yelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20(10):2429–40.38. Silverman L.R., Fenaux P., Mufti G.J. et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011;117(12):2697–702.Silverman L.R., Fenaux P., Mufti G.J. et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011;117(12):2697–702.39. Lyons R.M., Cosgriff T.M., Modi S.S. et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009;27(11):1850–6.Lyons R.M., Cosgriff T.M., Modi S.S. et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009;27(11):1850–6.40. Ziemba A., Hayes E., Freeman B.B. et al. Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine. Chemother Res Pract 2011;2011:965826.Ziemba A., Hayes E., Freeman B.B. et al. Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine. Chemother Res Pract 2011;2011:965826.41. Kantarjian H., Oki Y., Garcia-Manero G. et al. Results of a randomized study of three schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109(1):52–7.Kantarjian H., Oki Y., Garcia-Manero G. et al. Results of a randomized study of three schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109(1):52–7.42. Sekeres M.A., List A.F., Cuthbertson D. et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010;28(13):2253–8.Sekeres M.A., List A.F., Cuthbertson D. et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010;28(13):2253–8.43. Platzbecker U., Ganster C., Neesen J. et al. Safety and efficacy of a combination of 5-azacitidine followed by lenalidomide in high-risk MDS or AML patients with del(5q) cytogenetic abnormalities – results of the "AZALE" trial. ASH Annual Meeting Abstracts 2011. Blood 2011;118:3799.Platzbecker U., Ganster C., Neesen J. et al. Safety and efficacy of a combination of 5-azacitidine followed by lenalidomide in high-risk MDS or AML patients with del(5q) cytogenetic abnormalities – results of the "AZALE" trial. ASH Annual Meeting Abstracts 2011. Blood 2011;118:3799.44. Scott B.L., Ramakrishnan A., Storer B. et al. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. Br J Haematol 2010;148(6):944–7.Scott B.L., Ramakrishnan A., Storer B. et al. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. Br J Haematol 2010;148(6):944–7.45. Garcia-Manero G., Yang H., Bueso-Ramos C. et al. Phase 1 study of the histone deacetylase inhibitor vorinostat suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111(3):1060–6.Garcia-Manero G., Yang H., Bueso-Ramos C. et al. Phase 1 study of the histone deacetylase inhibitor vorinostat suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111(3):1060–6.46. Silverman L.R., Verma A., dchimar-Reissig R. et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium. 2008 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2008;26(15S):7000.Silverman L.R., Verma A., dchimar-Reissig R. et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium. 2008 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2008;26(15S):7000.47. Nand S., Godwin J., Smith S. et al. ydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma 2008;49(11):2141–7.Nand S., Godwin J., Smith S. et al. ydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma 2008;49(11):2141–7.